Sinopharm Group Co. Ltd. (HKG:1099)
18.38
-0.04 (-0.22%)
Mar 28, 2025, 4:08 PM HKT
Sinopharm Group Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
Revenue | 584,508 | 596,570 | 552,148 | 521,051 | 456,415 | Upgrade
|
Revenue Growth (YoY) | -2.02% | 8.04% | 5.97% | 14.16% | 7.32% | Upgrade
|
Cost of Revenue | 540,253 | 548,058 | 504,713 | 477,001 | 416,091 | Upgrade
|
Gross Profit | 44,255 | 48,512 | 47,434 | 44,051 | 40,323 | Upgrade
|
Selling, General & Admin | 25,582 | 26,161 | 24,914 | 23,210 | 21,203 | Upgrade
|
Other Operating Expenses | -468.62 | -582.01 | -676.16 | -589.19 | -652 | Upgrade
|
Operating Expenses | 26,436 | 26,193 | 24,670 | 23,067 | 21,221 | Upgrade
|
Operating Income | 17,819 | 22,318 | 22,764 | 20,984 | 19,102 | Upgrade
|
Interest Expense | -2,724 | -2,946 | -3,509 | -3,745 | -3,413 | Upgrade
|
Interest & Investment Income | 621.38 | 783.41 | 555.82 | 590.55 | 708.77 | Upgrade
|
Earnings From Equity Investments | 1,199 | 1,107 | 1,067 | 1,070 | 987.46 | Upgrade
|
Currency Exchange Gain (Loss) | -15.62 | -9.98 | -2.39 | -10.51 | 11.81 | Upgrade
|
Other Non Operating Income (Expenses) | -333.57 | -291.8 | -464.32 | -339.47 | -436.02 | Upgrade
|
EBT Excluding Unusual Items | 16,566 | 20,962 | 20,411 | 18,549 | 16,961 | Upgrade
|
Impairment of Goodwill | -931.2 | -27.02 | -38.98 | -396.06 | -156.29 | Upgrade
|
Gain (Loss) on Sale of Investments | -1,647 | -1,986 | -1,892 | -1,094 | -1,320 | Upgrade
|
Gain (Loss) on Sale of Assets | 79.91 | 492.31 | 3.11 | 65.87 | 152.96 | Upgrade
|
Asset Writedown | -174.76 | -27.88 | -16.81 | -210.8 | -108.81 | Upgrade
|
Other Unusual Items | 108.08 | 98.92 | 97.81 | 88.71 | 68.74 | Upgrade
|
Pretax Income | 14,001 | 19,512 | 18,564 | 17,003 | 15,598 | Upgrade
|
Income Tax Expense | 3,577 | 4,502 | 4,218 | 3,938 | 3,501 | Upgrade
|
Earnings From Continuing Operations | 10,424 | 15,010 | 14,345 | 13,065 | 12,097 | Upgrade
|
Minority Interest in Earnings | -3,374 | -5,956 | -5,820 | -5,306 | -4,910 | Upgrade
|
Net Income | 7,050 | 9,054 | 8,526 | 7,759 | 7,187 | Upgrade
|
Preferred Dividends & Other Adjustments | - | - | - | - | 0.07 | Upgrade
|
Net Income to Common | 7,050 | 9,054 | 8,526 | 7,759 | 7,187 | Upgrade
|
Net Income Growth | -22.13% | 6.19% | 9.89% | 7.95% | 14.95% | Upgrade
|
Shares Outstanding (Basic) | 3,117 | 3,117 | 3,117 | 3,121 | 3,111 | Upgrade
|
Shares Outstanding (Diluted) | 3,117 | 3,117 | 3,117 | 3,121 | 3,111 | Upgrade
|
Shares Change (YoY) | - | - | -0.12% | 0.30% | 4.70% | Upgrade
|
EPS (Basic) | 2.26 | 2.90 | 2.74 | 2.49 | 2.31 | Upgrade
|
EPS (Diluted) | 2.26 | 2.90 | 2.74 | 2.49 | 2.31 | Upgrade
|
EPS Growth | -22.13% | 6.19% | 10.02% | 7.63% | 10.00% | Upgrade
|
Free Cash Flow | 9,085 | 15,213 | 18,837 | 7,234 | 9,257 | Upgrade
|
Free Cash Flow Per Share | 2.92 | 4.88 | 6.04 | 2.32 | 2.98 | Upgrade
|
Dividend Per Share | 0.680 | 0.870 | 0.820 | 0.750 | 0.690 | Upgrade
|
Dividend Growth | -21.84% | 6.10% | 9.33% | 8.70% | 15.00% | Upgrade
|
Gross Margin | 7.57% | 8.13% | 8.59% | 8.45% | 8.83% | Upgrade
|
Operating Margin | 3.05% | 3.74% | 4.12% | 4.03% | 4.18% | Upgrade
|
Profit Margin | 1.21% | 1.52% | 1.54% | 1.49% | 1.57% | Upgrade
|
Free Cash Flow Margin | 1.55% | 2.55% | 3.41% | 1.39% | 2.03% | Upgrade
|
EBITDA | 20,175 | 24,404 | 24,777 | 22,896 | 20,882 | Upgrade
|
EBITDA Margin | 3.45% | 4.09% | 4.49% | 4.39% | 4.58% | Upgrade
|
D&A For EBITDA | 2,356 | 2,085 | 2,012 | 1,912 | 1,780 | Upgrade
|
EBIT | 17,819 | 22,318 | 22,764 | 20,984 | 19,102 | Upgrade
|
EBIT Margin | 3.05% | 3.74% | 4.12% | 4.03% | 4.18% | Upgrade
|
Effective Tax Rate | 25.55% | 23.07% | 22.72% | 23.16% | 22.44% | Upgrade
|
Updated Sep 25, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.